QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BIO

QT66Bio-Rad Laboratories, Inc.
NYSE·Healthcare·Medical - Devices·USA
Latest market price
282.44
-2.23-0.78%
OverviewShort InterestFilings
BIOQT66Bio-Rad Laboratories, Inc.·NYSE
OverviewShort InterestFilings
282.44-0.78%
TA
Loading chart...
Screen all →
ABT-0.10%$88.41ISRG+1.14%$406.78SYK+2.21%$307.80MDT+1.54%$79.34BSX+0.76%$45.29EW+0.78%$87.36DXCM+1.74%$72.47RMD+1.26%$188.63
Snapshot
Index-P/E45.46EPS (ttm)6.07
Insider Own8.84%
Shs Outstand26.76M
Perf Week-3.42%
Market Cap7.70BForward P/E28.34EPS next Y9.96Insider Trans0.02%Shs Float-Perf Month0.49%
Enterprise Value8.57BPEG-EPS next Q1.75Inst Own-Short Float-Perf Quarter6.58%
Income169.32MP/S2.97EPS this Y48.95%Inst Trans-Short Ratio-Perf Half Y-6.48%
Sales2.59BP/B1.12EPS next Y10.21%ROA1.72%Short Interest-Perf YTD-6.78%
Book/sh256.02P/C15.04EPS next 5Y11.07%ROE2.40%52W High343.10 -17.68%Perf Year22.55%
Cash/sh58.48P/FCF21.55EPS past 3/5Y-ROIC1.95%52W Low228.40 23.66%Perf 3Y-
Dividend Est.-EV/EBITDA18.24Sales past 3/5Y-2.68% 0.29%Gross Margin51.87%Volatility1.72% 2.05%Perf 5Y-
Dividend TTM-EV/Sales3.31EPS Y/Y TTM114.18%Oper. Margin9.25%ATR (14)9.31Perf 10Y-
Dividend Ex-Date-Quick Ratio2.37Sales Y/Y TTM0.90%Profit Margin6.52%RSI (14)45.41Recom2.50
Dividend Gr. 3/5Y-Current Ratio3.21EPS Q/Q-25.59%SMA20-4.74%Beta0.70Target Price321.67
Payout19.73%Debt/Eq0.20Sales Q/Q1.20%SMA50-0.34%Rel Volume1.03Prev Close284.67
Employees7,700LT Debt/Eq0.20EarningsJul 30SMA200-3.84%Avg Volume387.88KPrice282.44
IPO DateFeb 27, 1980Option/ShortYes / YesEPS/Sales Surpr.-5.03% 0.34%Net Debt/EBITDA1.85Volume398,184Change-0.78%
Analyst Ratings
DateActionAnalystRatingTarget
May-25-26ReiteratedWells FargoEqual Weight$290 → $310
May-14-26ResumedRBC CapitalOutperform$565 → $320
May-01-26ReiteratedWells FargoEqual Weight$320 → $290
Apr-07-26DowngradeCitigroupBuy → Neutral
Feb-16-26ReiteratedWells FargoEqual Weight$340 → $320
Feb-13-26ReiteratedUBSBuy$350 → $335
Oct-30-25ReiteratedWells FargoEqual Weight$340
Oct-01-24UpgradeCitigroupNeutral → Buy$400
Apr-03-24DowngradeCitigroupBuy → Neutral
Dec-07-22ReiteratedRBC CapitalOutperform$565
Latest News
Jun-17-26
Jun-17-2608:30PM
Global Fluorescent In Situ Hybridization Probe Market Size/Share Worth USD 2.27 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)Yahoo
Jun-11-26
Jun-11-2610:30AM
Global Next Generation Sequencing Services Market Size/Share Worth USD 56.1 Billion by 2035 at a 23.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)Yahoo
10:30AM
Global Next Generation Sequencing Services Market Size/Share Worth USD 56.1 Billion by 2035 at a 23.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)Yahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,5902,5832,567
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1,2471,2401,188
Gross Profit1,3421,3441,379
Selling, General and Administrative Excl. Other844820814
Research and Development261257296
Other Operating Expense-210
Operating Income239271269
Interest Expense494949
Unusual Expense
———
Non-Operating Income (Expense)-31-7742,563
Net Income Before Taxes222996-2,342
Income Taxes53236-498
Consolidated Net Income169760-1,844
Net Income From Continuing Operations169760-1,844
Net Income169760-1,844
EPS (Recurring)6.1127.87-65.36
EPS (Basic, Before Extraordinaries)6.1127.87-65.36
EPS (Diluted)6.0727.87-65.36
EBITDA4691,250-2,142
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio46.5310.87—
Price To Sales Ratio2.943.17—
Gross Margin51.8152.0353.72
Operating Margin9.2310.4910.48
Net Margin6.5329.42-71.83
Shares Outstanding272728
Market Capitalization7,6268,181—
Operating Lease Expense
———
Insider Trading Volume
$295.92$276.81$257.69$238.58$219.47● Close Price0.00K53.57K107.14K160.72K214.29KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ENGELHARDT EVA ANETTEEVP, President, CDGMay 11 '26Sale246.54550135,597346May 13 12:00 AM
Lakkaraju Roop KalyanEVP, Chief Financial OfficerApr 24 '26Option Exercise0.002,15602,984Apr 28 12:00 AM
ENLOE COURTNEY CEVP, General Counsel & SecApr 24 '26Option Exercise0.003720827Apr 28 12:00 AM
EDWARDS JEFFREY LDirectorApr 21 '26Option Exercise0.008140715Apr 23 12:00 AM
PINKSTON ARNOLD ADirectorApr 21 '26Option Exercise0.008140715Apr 23 12:00 AM
Hinckley Greg KDirectorApr 21 '26Option Exercise0.0081401,215Apr 23 12:00 AM
PEI MELINDA LITHERLANDDirectorApr 21 '26Option Exercise0.008140715Apr 23 12:00 AM
BARRY JAMESEVP, President, LSGNov 06 '25Sale306.18700214,289510Nov 10 12:00 AM
DiVincenzo Jonathan P.President & COOOct 24 '25Option Exercise0.003,73805,609Oct 28 12:00 AM
EVRAN SEDATEVP, Global Supply ChainOct 20 '25Option Exercise0.002,08802,568Oct 21 12:00 AM
BARRY JAMESEVP, President, LSGSep 01 '25Option Exercise0.001,2040749Sep 03 12:00 AM
Allison SchwartzDirectorSep 01 '25Option Exercise0.0029401,452Sep 03 12:00 AM
COREY COLLEENEVP, Global Human ResourcesSep 01 '25Option Exercise0.002,204019,581Sep 03 12:00 AM
SCHWARTZ NORMAN DChairman & CEOSep 01 '25Option Exercise0.0012,7060444,591Sep 03 12:00 AM
ENGELHARDT EVA ANETTEEVP, President, CDGJul 25 '25Option Exercise0.004900738Jul 29 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR